South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Both the India and GCC entities will be operated by separate dedicated management teams
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company has raised US$4.5 million in funding for its AI operating system
European operations' revenue grew 58.4% to Rs 599.7 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
